PD-L1 in breast cancer: comparative analysis of 3 different antibodies
- 1 February 2018
- journal article
- research article
- Published by Elsevier BV in Human Pathology
- Vol. 72, 28-34
- https://doi.org/10.1016/j.humpath.2017.08.010
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer CellsPLOS ONE, 2014
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic CancerClinical Cancer Research, 2007
- The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic FactorsNeoplasia, 2006
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996